1-(2-Diethylamino-ethyl)-1H-pyrazolo[3,4-b]quinoxalin-3-ylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(2-Diethylamino-ethyl)-1H-pyrazolo[3,4-b]quinoxalin-3-ylamine
• 英文别名: 1-[2-(diethylamino)ethyl]-1H-pyrazolo[3,4-b]quinoxalin-3-amine；1-[2-(diethylamino)ethyl]pyrazolo[4,3-b]quinoxalin-3-amine
• 化学式: C₁₅H₂₀N₆
• 分子量: 284.364
• InChiKey: QGLAXCCABAOQII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  72.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-氨基-1H-吡唑啉酮[3,4-b]喹喔啉 、 N,N-二乙基氯乙胺 在 potassium carbonate 作用下， 以 氯仿 为溶剂， 反应 240.0h， 生成 1-(2-Diethylamino-ethyl)-1H-pyrazolo[3,4-b]quinoxalin-3-ylamine
  参考文献：
  名称：

  Pyrazolo[3,4- b ]quinoxalines. A new class of cyclin-Dependent kinases inhibitors

  摘要：

  Protein kinases are involved in most physiological processes and in numerous diseases. Therefore. inhibitors of protein kinases have therefore a wide therapeutic potential. While screening for inhibitors of cyclin-depent kinases (CDK's) and glycogen synthase kinase-3 (GSK-3), we identified pyrazolo[3,4-b)]quinoxalines as sub-micromolar inhibitors of CDK1/cyclin B. A preliminary structure activity relationship study suggests that this family of compounds can be optimized to inhibit CDK's and GSK-3. Compounds ere tested For their anti-proliferative activity and the results show that several of them displayed a significant inhibitory effect on CDK1/cyclin B. The most active compound (1) as also tested against the brain kinases CDK5/p25 and GSK-3, and proved to be a good inhibitor of both of them. On the contrary, none of the compound,, showed any activity in the CDC25 phosphatase assay. As an additional approach, affinity chromatography on immobilized pyrazolo[3,4-b]quinoxalines will be used to identify the intracellular targets of this family of compounds. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00069-x

文献信息

• Pyrazolo[3,4- b ]quinoxalines. A new class of cyclin-Dependent kinases inhibitors
  作者：Miguel A. Ortega、Marı́a E. Montoya、Belén Zarranz、Andrés Jaso、Ignacio Aldana、Sophie Leclerc、Laurent Meijer、Antonio Monge

  DOI：10.1016/s0968-0896(02)00069-x

  日期：2002.7

  Protein kinases are involved in most physiological processes and in numerous diseases. Therefore. inhibitors of protein kinases have therefore a wide therapeutic potential. While screening for inhibitors of cyclin-depent kinases (CDK's) and glycogen synthase kinase-3 (GSK-3), we identified pyrazolo[3,4-b)]quinoxalines as sub-micromolar inhibitors of CDK1/cyclin B. A preliminary structure activity relationship study suggests that this family of compounds can be optimized to inhibit CDK's and GSK-3. Compounds ere tested For their anti-proliferative activity and the results show that several of them displayed a significant inhibitory effect on CDK1/cyclin B. The most active compound (1) as also tested against the brain kinases CDK5/p25 and GSK-3, and proved to be a good inhibitor of both of them. On the contrary, none of the compound,, showed any activity in the CDC25 phosphatase assay. As an additional approach, affinity chromatography on immobilized pyrazolo[3,4-b]quinoxalines will be used to identify the intracellular targets of this family of compounds. (C) 2002 Elsevier Science Ltd. All rights reserved.